View:
United States securities and exchange commission logo
June 11, 2020
David J. Woodhouse
Chief Executive Officer
NGM Biopharmaceuticals, Inc.
101 California Street, 5th Floor
San Francisco, California 94111
Re: NGM
Biopharmaceuticals, Inc.
Registration
Statement on Form S-3
Filed June 5, 2020
File No. 333-238991
Dear Dr. Woodhouse:
This is to advise you that we have not reviewed and will not
review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Courtney
Lindsay at (202) 5517237 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences